



Urology Cancer Recruitment Overview

Dr Mohini Varughese
Consultant Clinical Oncologist

April 2019


Business Intelligence Unit



Urology (Bladder, Prostate & Renal) - National ABF Category

RecruitmentDate_FinancialYear	FY1617						FY1718						FY1819					
	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank
East Midlands	63	172	143	88	466	14	18	235	167	47	467	12	79	195	102	35	411	13
Eastern	64	191	528	150	933	9	41	145	230	110	526	10	36	225	182	112	555	8
Greater Manchester	96	183	1426	98	1803	1	73	231	612	71	987	2	38	156	531	32	757	2
Kent, Surrey and Sussex	71	301	1081	97	1550	3	10	203	638	137	988	6	16	171	294	98	579	9
North East and North Cumbria	672	261	247	54	1234	2	373	213	139	48	773	3	493	81	47	9	630	5
North Thames	124	399	708	145	1376	10	187	523	357	74	1141	7	134	256	197	30	617	12
North West Coast	85	148	10	97	340	15	10	154	92	39	295	14	30	183	109	14	336	14
North West London	304	104	95	22	525	8	21	117	51	17	206	13	21	424	25	4	474	4
South London	86	405	264	334	1089	4	86	339	284	467	1176	1	79	331	298	381	1089	1
South West Peninsula	74	171	305	49	599	7	42	94	219	34	389	9	12	134	297	34	477	6
Thames Valley and South Midlands	34	134	560	14	742	5	26	57	442	6	531	5	22	76	281	16	395	7
Wessex	186	386	226	7	805	6	103	186	201	6	496	8	190	171	274	2	637	3
West Midlands	91	414	142	199	846	12	43	243	182	145	613	11	10	135	125	49	319	15
West of England	47	125	46	137	355	13	15	73	19	55	162	15	17	84	142	59	302	10
Yorkshire and Humber	61	500	554	57	1172	11	15	379	857	63	1314	4	101	337	135	27	600	11


Urology (Bladder, Prostate & Renal) – Trust Recruitment Overview



Sub-specialty: Bladder Cancer - National ABF Category

RecruitmentDate_FinancialYear	FY1617						FY1718						FY1819					
	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank
LCRN																		
East Midlands	9	62	137	0	208	11	9	66	136	0	211	9	58	47	44	0	149	6
Eastern	11	26	170	0	207	10	16	35	88	0	139	10	3	26	59	0	88	10
Greater Manchester	8	16	715	0	739	2	9	26	402	0	437	3	1	22	126	0	149	4
Kent, Surrey and Sussex	2	33	937	0	972	4	5	38	500	0	543	5	1	7	98	0	106	9
North East and North Cumbria	570	128	201	0	899	1	357	94	50	0	501	1	364	12	16	0	392	1
North Thames	54	32	315	0	401	9	117	95	131	0	343	8	36	53	27	0	116	13
North West Coast	27	38	0	0	65	13	8	27	70	0	105	12	8	10	81	0	99	7
North West London	303	49	79	0	431	5	12	15	44	0	71	11	18	5	24	0	47	11
South London	19	20	0	0	39	14	13	27	40	0	80	13	8	43	17	0	68	12
South West Peninsula	0	38	289	0	327	7	2	20	175	0	197	6	3	7	46	0	56	8
Thames Valley and South Midlands	3	23	478	0	504	3	22	19	343	0	384	2	15	25	183	0	223	2
Wessex	182	54	169	0	405	6	99	42	78	0	219	7	96	24	21	0	141	3
West Midlands	3	31	68	0	102	12	7	13	94	0	114	14	1	12	49	0	62	14
West of England	2	22	0	0	24	15	2	29	0	0	31	15	1	20	0	0	21	15
Yorkshire and Humber	16	95	528	0	639	8	3	93	689	0	785	4	97	41	132	0	270	5

Sub-specialty: Bladder Cancer – Trust Recruitment Overview



Bladder: A priority to enhance enrollment to trials

- NMIBC

- Immunotherapy for high risk disease
- Will require close liaison between oncology and urology (additional resource for oncology ++)

- MIBC

- Quality of Life After Bladder Cancer (Q-ABC) – easy win
 - Any patient undergoing potentially curative radical treatments for confirmed muscle invasive bladder cancer by either surgery or radiotherapy
- Bladder PATH
 - Image Directed Redesign of Bladder Cancer Treatment Pathways
 - RAIDER (Dose escalated, adaptive RT, to complete recruitment)


Bladder

- MIBC
 - Neoadjuvant studies of standard chemo +/- immunotherapy prior to cystectomy
 - RAD- IO
 - Radical CRT with durvalumab
- Metastatic disease
 - ATLANTIS (MAMs): maintenance vs placebo of rucaparib/ cabozantinb/ Enzalutamide
 - FORT: randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy

Sub-specialty: Prostate Cancer - National ABF Category

RecruitmentDate_FinancialYear	FY1617						FY1718						FY1819					
	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank
LCRN																		
East Midlands	54	94	5	88	241	14	4	156	30	47	237	13	13	134	58	35	240	12
Eastern	49	141	354	150	694	3	13	101	139	110	363	6	18	152	121	112	403	7
Greater Manchester	63	161	710	98	1032	1	24	202	205	71	502	2	15	119	395	32	561	3
Kent, Surrey and Sussex	67	256	143	97	563	8	2	163	137	137	439	4	7	164	195	98	464	8
North East and North Cumbria	102	118	32	54	306	10	15	112	86	48	261	8	122	67	29	9	227	9
North Thames	40	339	381	145	905	4	39	391	211	74	715	3	58	180	155	30	423	10
North West Coast	50	98	10	97	255	13	1	125	22	39	187	15	7	152	28	14	201	14
North West London	1	51	0	22	74	15	5	100	1	17	123	11	0	416	1	4	421	2
South London	53	368	212	334	967	2	57	300	143	467	967	1	67	276	229	381	953	1
South West Peninsula	63	119	16	49	247	9	3	69	44	34	150	10	1	127	251	34	413	4
Thames Valley and South Midlands	29	111	79	14	233	11	3	38	91	6	138	12	1	50	93	16	160	11
Wessex	2	315	57	7	381	5	0	137	119	6	262	5	88	144	247	2	481	5
West Midlands	83	380	73	199	735	6	36	229	87	145	497	9	5	122	76	49	252	15
West of England	39	86	46	137	308	7	8	39	19	55	121	14	8	64	142	59	273	6
Yorkshire and Humber	39	366	23	57	485	12	8	274	165	63	510	7	3	258	0	27	288	13

Sub-specialty: Prostate Cancer – Trust Recruitment Overview



Prostate

- Non metastatic
 - STAMINA - Supported exercise TrAining for Men wIth pros-tate caNcer on Androgen deprivation therapy
 - PIVOTAL Boost
 - ADD ASPIRIN
 - POPs
 - PACE – International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer Hormone sensitive locally advanced/ metastatic
- Hormone Sensitive prostate cancer
 - STAMPEDE (currently oestrogen patch vs metformin)
 - Future arms to involve radium, ? SABR to 5 metastatic sites

Prostate

- mCRPC
 - ACE (measurement of cognitive function Enzalutamide vs Abiraterone)
 - CTC stop (due to be stopped early)
 - TOPARP
 - Immunotherapy studies
 - Keynote 010 pembrolizumab + olaparib vs abi/ enza
 - Key note 641 pembrolizumab + enza vs placebo + enzalutamide
 - MAESTRO: **M**olecular stratification profiling protocol in metastatic **C**astration **R**esistant **P**rostate Cancer (mCRPC)
 - PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab for Patients Suffering from Metastatic Prostate Cancer

Sub-specialty: Renal Cancer - National ABF Category

RecruitmentDate_FinancialYear	FY1617						FY1718						FY1819					
	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	Obs.	Large Scale	Total	Adj. for Pop. Rank
LCRN																		
East Midlands	0	16	1	0	17	12	5	13	1	0	19	8	8	14	0	0	22	9
Eastern	4	24	4	0	32	9	12	9	3	0	24	5	15	47	2	0	64	2
Greater Manchester	25	6	1	0	32	4	40	3	5	0	48	3	22	15	10	0	47	3
Kent, Surrey and Sussex	2	12	1	0	15	13	3	2	1	0	6	13	8	0	1	0	9	14
North East and North Cumbria	0	15	14	0	29	5	1	7	3	0	11	11	7	2	2	0	11	10
North Thames	30	28	12	0	70	2	31	37	15	0	83	4	40	23	15	0	78	4
North West Coast	8	12	0	0	20	11	1	2	0	0	3	14	15	21	0	0	36	5
North West London	0	4	16	0	20	6	4	2	6	0	12	6	3	3	0	0	6	13
South London	14	17	52	0	83	1	16	12	101	0	129	1	4	12	52	0	68	1
South West Peninsula	11	14	0	0	25	3	37	5	0	0	42	2	8	0	0	0	8	11
Thames Valley and South Midlands	2	0	3	0	5	14	1	0	8	0	9	10	6	1	5	0	12	8
Wessex	2	17	0	0	19	10	4	7	4	0	15	7	6	3	6	0	15	7
West Midlands	5	3	1	0	9	15	0	1	1	0	2	15	4	1	0	0	5	15
West of England	6	17	0	0	23	7	5	5	0	0	10	9	8	0	0	0	8	12
Yorkshire and Humber	6	39	3	0	48	8	4	12	3	0	19	12	1	38	3	0	42	6

CRN;SWP priorities

- Enhance recruitment to radiotherapy trials
 - Funding to follow for each centre
- Trials to consider opening at each site
 - QABC, Bladder PATH (operating centres), RAD-IO, ATLANTIS,
 - STAMINA, PIVOTAL Boost, PACE
 - RAMPART
- Enhance cross trust referral
 - e.g. TOPARP,
 - NAC immunotherapy studies at cystectomy centres
 - Prostate immunotherapy studies
 - Immunotherapy for NIBC?

